With deal for Tizona, Gilead places latest bet on cancer immunosuppression

As its investors get partial exit, deal gives Tizona $300M up front, chance to reach clinical POC

For the second time in as many months, Gilead has made a large investment in a biotech in the cancer immunosuppression area, paying $300 million up front to acquire nearly half of privately-held Tizona with an exclusive option to buy the rest after a clinical readout.

The deal gives Gilead Sciences Inc. (NASDAQ:GILD) a chance to gain full ownership of TTX-080, a first-in-class antibody that inhibits immune checkpoint HLA-G. Tizona plans to begin a

Read the full 734 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers